Takeda Pharmaceutical Company Limited
NYSE:TAK · New York Stock Exchange
+$0.18 today
Vol 2.05M · Avg 3.08M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $203.3B +88.4% | $107.9B -25.1% | $144.1B -54.6% | $317.0B +37.7% | $230.2B | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $764.6B +0.4% | $761.4B +4.6% | $728.0B +9.6% | $664.4B +13.9% | $583.2B | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $0 -100.0% | $66.9B +173.2% | -$91.4B -257.5% | $58.1B -19.8% | $72.4B | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $0 -100.0% | $72.9B +2.8% | $70.9B +16.8% | $60.7B +39.9% | $43.4B | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | -$265.0B -407.1% | -$52.3B +79.6% | -$256.0B -913.3% | -$25.3B -125.6% | $98.6B | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | -$74.4B -26.2% | -$59.0B -490.4% | $15.1B -79.9% | $75.1B -41.0% | $127.3B | $592.6M | $1.3B | $626.2M |
| Inventory | -$65.0B -85.8% | -$35.0B +69.8% | -$115.7B -46.2% | -$79.2B -71.5% | -$46.1B | $1.0B | $1.2B | $1.1B |
| Accounts Payables | -$3.3B | $0 +100.0% | -$9.9B +81.4% | -$53.1B -170.3% | $75.5B | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | -$122.3B -393.4% | $41.7B +128.7% | -$145.5B -556.0% | $31.9B +154.9% | -$58.1B | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | $292.4B +74.8% | $167.2B +38.4% | $120.8B +223.6% | -$97.7B -202.5% | $95.4B | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | $995.3B -5.9% | $1.1T +47.6% | $716.3B -26.7% | $977.2B -13.0% | $1.1T | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$186.6B +7.1% | -$200.8B +58.2% | -$480.7B +24.1% | -$633.7B -240.6% | -$186.0B | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $42.2B -45.4% | $77.2B +1731.3% | -$4.7B -159.5% | $8.0B +137.1% | -$21.5B | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | -$17.5B +84.3% | -$111.4B -178.0% | -$40.1B -294.7% | -$10.2B -21.7% | -$8.3B | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $8.4B -71.5% | $29.4B +267.1% | $8.0B -64.0% | $22.3B +31.5% | $16.9B | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | -$8.5B +94.9% | -$166.3B +33.9% | -$251.7B -3956.3% | $6.5B +707.7% | $808.0M | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | -$411.2B -12.0% | -$367.1B +20.9% | -$463.9B +23.6% | -$607.1B -206.4% | -$198.1B | $4.8B | $6.4B | $5.1B |
| Debt Repayment | $46.5B +114.8% | -$314.3B -20874.2% | $1.5B +100.5% | -$285.1B +52.5% | -$600.5B | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $0 | $0 | $0 | $0 | $0 | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | -$54.7B -5.5% | -$51.9B -2129.6% | -$2.3B +91.4% | -$26.9B +65.3% | -$77.5B | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | -$330.7B -9.3% | -$302.5B -5.3% | -$287.2B -2.8% | -$279.4B +1.5% | -$283.7B | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | -$59.1B +28.5% | -$82.8B -24.6% | -$66.4B +43.6% | -$117.7B -8.4% | -$108.6B | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | -$398.1B +47.0% | -$751.4B -112.0% | -$354.4B +50.0% | -$709.1B +33.7% | -$1.1T | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $161.8B +1521.5% | -$11.4B -143.4% | $26.2B +14.3% | $22.9B -20.3% | $28.8B | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | $347.9B +578.6% | -$72.7B +4.0% | -$75.7B +76.0% | -$316.2B -171.3% | -$116.5B | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | $808.7B -5.6% | $856.4B +263.5% | $235.6B -31.4% | $343.5B -63.3% | $937.1B | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Cardinal Health, Inc.
NYSE:CAH
$52.27B
Becton, Dickinson and Company
NYSE:BDX
$52.17B
Edwards Lifesciences Corporation
NYSE:EW
$50.20B
Haleon plc
NYSE:HLN
$39.49B
Agilent Technologies, Inc.
NYSE:A
$35.96B
Alcon Inc.
NYSE:ALC
$31.49B
IQVIA Holdings Inc.
NYSE:IQV
$27.93B
ResMed Inc.
NYSE:RMD
$27.22B
Veeva Systems Inc.
NYSE:VEEV
$24.76B
Insmed Incorporated
NASDAQ:INSM
$20.55B
SEC Filings
Recent regulatory filings
No filings found.
Does TAK generate free cash flow?
Takeda Pharmaceutical Company Limited (TAK) generated $808.70B of free cash flow in fiscal 2025.
How much operating cash flow does TAK produce?
Operating cash flow was $995.32B, before capital expenditures of $186.62B.
Explore More
Continue the stock analysis
Jump to another research area for this company.